Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2000
12/21/2000DE19927688A1 Multi-layered tablet containing tramadole and diclofenac, useful for treating pain, has separating layer between active ingredient layers
12/21/2000CA2378745A1 Ligand-conjugated oligomeric compounds
12/21/2000CA2377232A1 Prophylactic, therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions
12/21/2000CA2376956A1 Charged compounds facilitate viral transduction of cells
12/21/2000CA2376921A1 Nasal delivery of apomorphine
12/21/2000CA2376865A1 Compositions and methods comprising morphine gluconate
12/21/2000CA2376217A1 Novel formulations comprising lipid-regulating agents
12/21/2000CA2375576A1 Gel composition for filing a breast milk duct prior to surgical excision of the duct or other breast tissue
12/21/2000CA2375551A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
12/21/2000CA2375346A1 Fibrin sealant as a transfection/transformation vehicle for gene therapy
12/21/2000CA2372558A1 Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
12/21/2000CA2340375A1 Agent for enhancing accumulation of drugs in tumor tissues
12/21/2000CA2340120A1 Transdermally delivered aspirin
12/20/2000EP1061085A2 Synthetic catalytic oligonucleotides
12/20/2000EP1060750A2 Method for treating amyloidosis
12/20/2000EP1060749A1 Aqueous pharmaceutical composition comprising Tezosentan
12/20/2000EP1060734A2 Use of cyclic enamines as sun protection agents
12/20/2000EP1060732A2 Novel topical formulations comprising vesicle delivery systems
12/20/2000EP1060192A2 Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
12/20/2000EP1059943A1 Implantable particles for tissue bulking and the treatment of gastroesophageal reflux disease, urinary incontinence, and skin wrinkles
12/20/2000EP1059942A2 Pharmaceutical compositions containing cyclodextrins and taxoids
12/20/2000EP1059941A1 Pharmaceutical compositions and their use
12/20/2000EP1059935A1 Mucosal microparticle conjugate vaccine
12/20/2000EP1059931A2 Utilization of cd137 in order to promote the proliferation of peripheral monocytes
12/20/2000EP1059928A1 Inorganic nitrite and organic acid in combination as topical antiviral composition
12/20/2000EP1059918A1 Novel dosage form
12/20/2000EP1059916A1 Extended release dosage form
12/20/2000EP1059915A1 Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents
12/20/2000EP1059913A1 Emulsion preconcentrates containing cyclosporin or a macrolide
12/20/2000EP1059911A1 Formulations with an anti-viral effect
12/20/2000EP0822807B1 Gel with increased oxygen content
12/20/2000EP0771190A4 Lock and key micelles
12/20/2000EP0754030B1 Method for stabilizing duocarmycin derivatives
12/20/2000EP0628034B1 N- (1,3,5-triazine-2-yl)aminocarbonyl]benzene sulphonamide herbicides
12/20/2000CN1277613A Poly (ADP-ribose) polymerase ('PARP') inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
12/20/2000CN1059705C Composition for introducing nucleic acid complexes into higher eucaryotic cells
12/19/2000US6162834 Foaming oil-in-water emulsion based on nonionic surfactants, a fatty phase and a crosslinked cationic or anionic polymer, and its use in topical applications
12/19/2000US6162833 Photostable aqueous solution comprising benzyl alcohol derivatives
12/19/2000US6162774 Mixture of salicylic acid, maleic acid and pyruvic acid with detergent base
12/19/2000US6162629 Preparing a serine protease solution; eluting protease from column, freeze drying, filtering and recovering protease
12/19/2000US6162469 A medical powder comprising a base particle of a ferromagnetic metal having thereon at least one metal oxide layer, and an outside coating containing bioinert polymeric or copolymeric layer and a drug or medical component
12/19/2000US6162462 Incubating a bupivacaine solution at a controlled ph which prevents its precipitation, with a suspension of giant multivescular liposomes having greater concentration of ammonium ions inside than outside, removing non-capsulated
12/19/2000US6162459 Acyclovir transdermal delivery system
12/19/2000US6162448 Polyalkylenepolyamine provides heat and oxidation stability to retinoid; treating or preventing inflammation, immunosuppression, irritation, or acne of the skin
12/19/2000US6162447 Cosmetic comprising oil phase of given particle size dispersed in aqueous phase comprising given weight percent of a beta-1,3-glucan of given molecular weight range; excludes compositions comprising a surfactant; storage stability
12/19/2000US6162241 Hemostatic tissue sealants
12/19/2000CA2234826C Fluoxetine enteric pellets
12/19/2000CA2184822C Intranasal antimigraine composition
12/19/2000CA2174658C Novel composition
12/14/2000WO2000075333A1 Streptavidin expressed gene fusions and methods of use thereof
12/14/2000WO2000075284A1 A bacterial strain, processed plant extracts and probiotic compositions for human and veterinary use
12/14/2000WO2000075176A1 Small cyclic mimics of brain-derived neurotrophic factor (bdnf)
12/14/2000WO2000075174A1 Heart homing peptides and methods of using same
12/14/2000WO2000075162A1 A compound containing a labile disulfide bond
12/14/2000WO2000075126A1 Mycolactone and related compounds, compositions and methods of use
12/14/2000WO2000075105A1 Valency platform molecules comprising aminooxy groups
12/14/2000WO2000074933A1 Composite laminate and method for its production
12/14/2000WO2000074736A1 Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
12/14/2000WO2000074729A2 Alpha or beta emitters to fragments in radioimmunotherapy
12/14/2000WO2000074724A2 Conjugates comprising cytokines and nucleic acids for treating proliferating cells
12/14/2000WO2000074722A2 Modification of biological elements
12/14/2000WO2000074721A1 Vitamin directed dual targeting therapy
12/14/2000WO2000074718A1 Immunotherapy of autoimmune disorders using antibodies which target b-cells
12/14/2000WO2000074712A2 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
12/14/2000WO2000074709A2 Modified biodegradable polyester microspheres for stabilizing and improving the release profile of drugs encapsulated within the microspheres
12/14/2000WO2000074677A2 Improved pharmaceutical formulations
12/14/2000WO2000074670A1 USE OF VERAPAMIL AND VERAPAMIL DERIVATIVES FOR PRODUCING MEDICAMENTS WITH AN INHIBITING EFFECT ON β-GLUCURONIDASE IN HUMAN TISSUE
12/14/2000WO2000074668A1 Non-solid composition for local application
12/14/2000WO2000074659A1 Morphine sulphate microgranules, method for preparing same and compositions containing same
12/14/2000WO2000074658A1 Use of drug-loaded nanoparticles for the treatment of cancers
12/14/2000WO2000074654A1 Novel preparation and administration form comprising an acid-labile active compound
12/14/2000WO2000074653A1 Oil-core compositions for the sustained release of hydrophobic drugs
12/14/2000WO2000074652A1 Pharmaceutical composition for nasally administering water-soluble active substances
12/14/2000WO2000074651A1 Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water
12/14/2000WO2000074650A2 Implantable gel compositions and method of manufacture
12/14/2000WO2000074646A2 Novel liposomal vector complexes and their use in gene therapy
12/14/2000WO2000047229A3 Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
12/14/2000WO2000047190A3 Method for producing film-type dosage forms
12/14/2000WO2000045855A3 Diagnostic imaging of lymph structures
12/14/2000WO2000045841A3 Human papilloma virus vaccine formulations
12/14/2000WO2000045770A3 Compressed lecithin preparations
12/14/2000WO2000044393A3 Buccal delivery system for proteinaceous medicaments
12/14/2000WO2000044348A3 Materials and methods for making improved micelle compositions
12/14/2000WO2000040203A3 Polymeric delivery agents and delivery agent compounds
12/14/2000DE19926779A1 Verwendung von substituierten Vinyl-tetrahydronaphthalinen und Vinyl-benzotetrahydropyranen als Lichtschutzmittel Use of substituted vinyl-tetrahydronaphthalenes and vinyl benzotetrahydropyranen as light stabilizers
12/14/2000DE19926475A1 Träger-Pharmaka-Konjugate Carrier conjugates drugs
12/14/2000DE19926154A1 Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung A process for producing an injectable medicament preparation
12/14/2000DE19925810A1 Anwendung von Verapamil und Verapamilderivaten zur Herstellung von Arzneimitteln mit Glucuronidase hemmender Wirkung Application of verapamil and Verapamilderivaten for producing drugs with glucuronidase inhibiting action
12/14/2000CA2376729A1 Small cyclic mimics of brain-derived neurotrophic factor (bdnf)
12/14/2000CA2376199A1 Use of verapamil and verapamil derivatives for producing medicaments with an inhibiting effect on .beta.-glucuronidase in human tissue
12/14/2000CA2376192A1 Streptavidin expressed gene fusions and methods of use thereof
12/14/2000CA2376175A1 Vitamin directed dual targeting therapy
12/14/2000CA2376057A1 Valency platform molecules comprising aminooxy groups
12/14/2000CA2376048A1 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
12/14/2000CA2376010A1 Mycolactone and related compounds, compositions and methods of use
12/14/2000CA2375914A1 Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
12/14/2000CA2375912A1 Immunotherapy of autoimmune disorders using antibodies which target b-cells
12/14/2000CA2375854A1 Novel liposomal vector complexes and their use in gene therapy
12/14/2000CA2375371A1 Oil-core compositions for the sustained release of hydrophobic drugs
12/14/2000CA2374001A1 Alpha or beta emitters attached to fragments in radioimmunotherapy
1 ... 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 ... 1712